TPIV Is Back On Watch For Thursday!

Sign Up For Our FREE E-mail Newsletter-> HERE <-To Receive Our Penny Stock Expert Picks Now!

Visit our Twitter page for real-time updates, click here: Penny Stock Experts

Hi Everyone & Welcome New Subscribers,

Last night we didn’t get a chance to upload our full watch list, so we posted a quick list on our Twitter page, but that’s alright considering what we would’ve watched didn’t make earth shattering moves. That’s been the mantra for OTCs lately, and basically this entire year, as the “wild west” of small caps continues to look for a reason to gain real volume.

TPIV (TapImmune, Inc.) has weathered the storm, however, like many biotechs, trading up to a high of $1.70 this year following early results related to their breast cancer vaccine, which is now being funded in part by the U.S. Dept. of Defense. Read the full press release related to the DoD’s grant, HERE, and keep the stock on top of your speculative buy watch list as the company moves into later stage clinical trials and results are made available.

It is still our intention to release a full report/e-mail alert to our subscribers, but anyone who has followed us for any amount of time knows how important we feel timing is.

The time will come, and we will alert TPIV on a broader scale, but for now the stock is in an accumulation phase, which could mean even bigger gains for those who stick their neck out there and experiment early, but also presents greater risks.

Considering the stock closed at today’s high of .59, and is just a couple cents off this week’s high of .615, we could see this accumulation phase come to an end rather quickly over the short term.

Keep this stock on the tippity-top of your watch list!

Happy Trading!

Sign up-> NOW <-To Join Our E-mail List!

Happy Trading!


The Penny Stock Experts Team At

Please read our legal Disclaimer below:

We continue trade up to 20,000 shares of TPIV which we have purchased on the open market with our own money. We have no communication with the company nor any affiliates. We may add to this position or sell it entirely at any time.

This disclaimer is to be read in its entirety, and fully understood before using or joining the email list. reserves the right to revise, amend, or modify our Privacy Policy, our Disclaimer, and our other policies and agreements at any time and in any manner by updating their postings. You are responsible for regularly reviewing these terms, conditions, and notices, and any additional terms posted on Your continued use of the website and/or email newsletter after the effective date of such changes constitutes your acceptance of and agreement to such changes. If we should update this disclaimer, we will post the updates to this page on DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS.

Neither nor any of its employees, affiliates, subsidiaries, or family members are registered investment advisers or registered st ock brokers either within the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority and shall not be liable for any direct, indirect, incidental, special or consequential damages arising out of, or resulting from the use or inability to use this site, including but not limited to damages for the loss of capital, funds, profits, use, data, or any and all other possible damages, even if such party has been advised of the possibility of such damages resulting from the use of this site and all information contained on this site.

We are neither licensed nor qualified to provide investment advice. The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the company’s profiled based solely on information contained in our newsletter or website.

Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research. may buy or sell shares on the open market that may positively or negatively affect the stock price before or after this mailing and subscribers are to be fully aware that and it’s affiliates can buy or sell more shares at any time. We can add or decrease this position at anytime following this e-mail or post. and/or it’s affiliates may receive compensation for e-mail alerts.

To view our full compensation disclosure please visit does not accept free-trading shares as a form of payment.